Paradigm Biopharmaceuticals Limited

OTCPK:PBIG.F Stock Report

Market Cap: US$74.0m

Paradigm Biopharmaceuticals Valuation

Is PBIG.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PBIG.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PBIG.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PBIG.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PBIG.F?

Key metric: As PBIG.F is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for PBIG.F. This is calculated by dividing PBIG.F's market cap by their current book value.
What is PBIG.F's PB Ratio?
PB Ratio4.8x
BookAU$23.81m
Market CapAU$113.87m

Price to Book Ratio vs Peers

How does PBIG.F's PB Ratio compare to its peers?

The above table shows the PB ratio for PBIG.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.5x
GNLX Genelux
2.6x12.0%US$87.0m
INO Inovio Pharmaceuticals
1.4x26.2%US$106.2m
AVTX Avalo Therapeutics
5x-17.9%US$106.0m
ANIX Anixa Biosciences
4.7x9.5%US$103.0m
PBIG.F Paradigm Biopharmaceuticals
4.8x8.8%US$113.9m

Price-To-Book vs Peers: PBIG.F is expensive based on its Price-To-Book Ratio (4.8x) compared to the peer average (3.5x).

Price to Book Ratio vs Industry

How does PBIG.F's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$554.58m
IMAB I-Mab
0.4x1.8%US$76.59m
ACET Adicet Bio
0.4x6.7%US$74.16m
MGX Metagenomi
0.3x-23.2%US$70.73m
PBIG.F 4.8xIndustry Avg. 1.9xNo. of Companies81PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: PBIG.F is expensive based on its Price-To-Book Ratio (4.8x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is PBIG.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PBIG.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PBIG.F's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PBIG.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$0.46
0%
31.9%US$0.61US$0.32n/a2
Nov ’25US$0.14
US$0.46
+230.8%
31.9%US$0.61US$0.32n/a2
Oct ’25US$0.11
US$0.46
+305.2%
31.9%US$0.61US$0.32n/a2
May ’25US$0.18
US$1.45
+708.1%
39.0%US$2.01US$0.88n/a2
Apr ’25n/a
US$1.45
0%
39.0%US$2.01US$0.88n/a2
Mar ’25n/a
US$1.45
0%
39.0%US$2.01US$0.88n/a2
Feb ’25US$0.20
US$1.45
+641.2%
39.0%US$2.01US$0.88n/a2
Jan ’25US$0.27
US$1.45
+429.2%
39.0%US$2.01US$0.88n/a2
Dec ’24US$0.26
US$1.45
+460.0%
39.0%US$2.01US$0.88n/a2
Nov ’24US$0.43
US$1.45
+237.0%
39.0%US$2.01US$0.88US$0.142
Oct ’24n/a
US$1.81
0%
18.4%US$2.14US$1.48US$0.112
Sep ’24US$0.41
US$1.81
+342.6%
18.4%US$2.14US$1.48n/a2
Aug ’24US$0.67
US$1.81
+169.8%
18.4%US$2.14US$1.48US$0.182
Jul ’24n/a
US$1.81
0%
18.4%US$2.14US$1.48US$0.192
Jun ’24n/a
US$1.81
0%
18.4%US$2.14US$1.48n/a2
May ’24US$0.76
US$1.81
+137.3%
18.4%US$2.14US$1.48US$0.182
Apr ’24US$0.95
US$1.81
+90.3%
18.4%US$2.14US$1.48n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.91

7D

0.6%

1Y

9.8%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

7D

4.7%

1Y

-4.8%